Citations to this article
Abstract
The identification of targetable vulnerabilities in the context of therapeutic resistance is a key challenge in cancer treatment. We detected pervasive aberrant splicing as a characteristic feature of chronic lymphocytic leukemia (CLL), irrespective of splicing factor mutation status, which was associated with sensitivity to the spliceosome modulator, E7107. Splicing modulation affected CLL survival pathways, including members of the B cell lymphoma-2 (BCL2) family of proteins, remodeling antiapoptotic dependencies of human and murine CLL cells. E7107 treatment decreased myeloid cell leukemia-1 (MCL1) dependence and increased BCL2 dependence, sensitizing primary human CLL cells and venetoclax-resistant CLL-like cells from an Eμ-TCL1–based adoptive transfer murine model to treatment with the BCL2 inhibitor venetoclax. Our data provide preclinical rationale to support the combination of venetoclax with splicing modulators to reprogram apoptotic dependencies in CLL for treating venetoclax-resistant CLL cases.
Authors
Elisa ten Hacken, Rebecca Valentin, Fara Faye D. Regis, Jing Sun, Shanye Yin, Lillian Werner, Jing Deng, Michaela Gruber, Jessica Wong, Mei Zheng, Amy L. Gill, Michael Seiler, Peter Smith, Michael Thomas, Silvia Buonamici, Emanuela M. Ghia, Ekaterina Kim, Laura Z. Rassenti, Jan A. Burger, Thomas J. Kipps, Matthew L. Meyerson, Pavan Bachireddy, Lili Wang, Robin Reed, Donna Neuberg, Ruben D. Carrasco, Angela N. Brooks, Anthony Letai, Matthew S. Davids, Catherine J. Wu
Citation information
Citations to this article (35)
| Title and authors | Publication | Year |
|---|---|---|
|
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia.
Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D |
Haematologica | 2025 |
|
The ncBAF complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia
Daniel Hägerstrand, Blaz Oder, Diego Cortese, Ying Qu, Amrei Binzer-Panchal, Cecilia Österholm, Teresa Peso-Santos, Leily Rabbani, Hassan Asl, Aron Skaftason, Viktor Ljungström, August Lundholm, Maria Koutroumani, Zahra Haider, Cecilia Jylhä, John Mollstedt, Larry Mansouri, Karla Plevova, Andreas Agathangelidis, Lydia Scarfò, Marine Armand, Alice Muggen, Neil Kay, Tait Shanafelt, Davide Rossi, Lukas Orre, Sarka Pospisilova, Konstantin Barylyuk, Frederic Davi, Mattias Vesterlund, Anton Langerak, Janne Lehtiö, Paolo Ghia, Kostas Stamatopoulos, Lesley-Ann Sutton, Richard Rosenquist |
Leukemia | 2024 |
|
Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML
Wheeler EC, Martin BJ, Doyle WC, Neaher S, Conway CA, Pitton CN, Gorelov RA, Donahue M, Jann JC, Abdel-Wahab O, Taylor J, Seiler M, Buonamici S, Pikman Y, Garcia JS, Belizaire R, Adelman K, Tothova Z |
Science Translational Medicine | 2024 |
|
Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia
Mavridou D, Psatha K, Aivaliotis M |
Journal of Personalized Medicine | 2024 |
|
The Impact of Spliceosome Inhibition in SF3B1-Mutated Uveal Melanoma.
Nguyen JQN, Drabarek W, Leeflang AMCHJ, Brands T, van den Bosch TPP, Verdijk RM, van de Werken HJG, van Riet J, Paridaens D, de Klein A, Brosens E, Kiliç E |
Investigative ophthalmology & visual science | 2024 |
|
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.
Zheng S, Tong Y, Yang L, Chen J, Tan Y |
Annals of hematology | 2024 |
|
Targeting splicing for hematological malignancies therapy.
Szelest M, Giannopoulos K |
BMC genomics | 2024 |
|
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia
Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez II JR, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers KA, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D |
Haematologica | 2024 |
|
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
Luo MX, Tan T, Trussart M, Poch A, Nguyen TM, Speed TP, Hicks DG, Bandala-Sanchez E, Peng H, Chappaz S, Slade C, Utzschneider DT, Koldej RM, Ritchie D, Strasser A, Thijssen R, Ritchie ME, Tam CS, Lindeman GJ, Huang DC, Lew TE, Anderson MA, Roberts AW, Teh CE, Gray DH |
Blood | 2024 |
|
Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma
Tran S, Sipila P, Frigault MM, Stelte-Ludwig B, Johnson AJ, Birkett J, Izumi R, Hamdy A, Maity R, Bahlis NJ, Neri P, Narendran A |
Blood Neoplasia | 2024 |
|
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
Aptullahoglu E, Ciardullo C, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J |
International journal of molecular sciences | 2023 |
|
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities.
Ten Hacken E, Sewastianik T, Yin S, Hoffmann GB, Gruber M, Clement K, Penter L, Redd RA, Ruthen N, Hergalant S, Sholokhova A, Fell G, Parry EM, Broséus J, Guieze R, Lucas F, Hernández-Sánchez M, Baranowski K, Southard J, Joyal H, Billington L, Regis FFD, Witten E, Uduman M, Knisbacher BA, Li S, Lyu H, Vaisitti T, Deaglio S, Inghirami G, Feugier P, Stilgenbauer S, Tausch E, Davids MS, Getz G, Livak KJ, Bozic I, Neuberg DS, Carrasco RD, Wu CJ |
2023 | |
|
Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models
Penter L, ten Hacken E, Southard J, Lareau CA, Ludwig LS, Li S, Neuberg DS, Livak KJ, Wu CJ |
Cancer research | 2023 |
|
Emerging Therapies in CLL in the Era of Precision Medicine.
Iyer P, Wang L |
Cancers | 2023 |
|
Global Shift in Alternative Splicing and Therapeutic Susceptibilities in Leukemia Driven by METTL3 Overexpression
Janin M, Esteller M |
2023 | |
|
METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Wu Y, Jin M, Fernandez M, Hart KL, Liao A, Ge X, Fernandes SM, McDonald T, Chen Z, Röth D, Ghoda LY, Marcucci G, Kalkum M, Pillai RK, Danilov AV, Li JJ, Chen J, Brown JR, Rosen ST, Siddiqi T, Wang L |
2023 | |
|
Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.
Morales ML, García-Vicente R, Rodríguez-García A, Reyes-Palomares A, Vincelle-Nieto Á, Álvarez N, Ortiz-Ruiz A, Garrido-García V, Giménez A, Carreño-Tarragona G, Sánchez R, Ayala R, Martínez-López J, Linares M |
Leukemia | 2023 |
|
Pre-mRNA splicing-associated diseases and therapies
Love SL, Emerson JD, Koide K, Hoskins AA |
RNA biology | 2023 |
|
SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia.
López-Oreja I, Gohr A, Playa-Albinyana H, Giró A, Arenas F, Higashi M, Tripathi R, López-Guerra M, Irimia M, Aymerich M, Valcárcel J, Bonnal S, Colomer D |
Life science alliance | 2023 |
|
Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model
F Severin, A Urbani, T Varanita, M Bachmann, M Azzolini, V Martini, M Pizzi, A Tos, F Frezzato, A Mattarei, P Ghia, M Bertilaccio, E Gulbins, C Paradisi, M Zoratti, G Semenzato, L Leanza, L Trentin, I Szabò |
Journal of Experimental & Clinical Cancer Research | 2022 |
|
The role of NPM1 alternative splicing in patients with chronic lymphocytic leukemia.
Szelest M, Masternak M, Zając M, Chojnacki M, Skórka K, Zaleska J, Karczmarczyk A, Stasiak G, Wawrzyniak E, Kotkowska A, Siemieniuk-Ryś M, Purkot J, Subocz E, Cichocka E, Tomczak W, Zawirska D, Giannopoulos K |
PloS one | 2022 |
|
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia
Wang E, Pineda JM, Kim WJ, Chen S, Bourcier J, Stahl M, Hogg SJ, Bewersdorf JP, Han C, Singer ME, Cui D, Erickson CE, Tittley SM, Penson AV, Knorr K, Stanley RF, Rahman J, Krishnamoorthy G, Fagin JA, Creger E, McMillan E, Mak CC, Jarvis M, Bossard C, Beaupre DM, Bradley RK, Abdel-Wahab O |
Cancer Cell | 2022 |
|
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R |
Leukemia | 2022 |
|
Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities
M Blijlevens, J Li, VW van Beusechem |
International journal of molecular sciences | 2021 |
|
Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML
M Sevin, F Debeurme, L Laplane, S Badel, M Morabito, HL Newman, M Torres-Martin, Q Yang, B Badaoui, O Wagner-Ballon, V Saada, D Sélimoglu-Buet, L Kraus-Berthier, S Banquet, A Derreal, P Fenaux, R Itzykson, T Braun, G Etienne, C Berthon, S Thépot, O Kepp, G Kroemer, E Padron, ME Figueroa, N Droin, E Solary |
Blood | 2021 |
|
Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets
I López-Oreja, H Playa-Albinyana, F Arenas, M López-Guerra, D Colomer |
Cancers | 2021 |
|
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
M Stahl, K Menghrajani, A Derkach, A Chan, W Xiao, J Glass, AC King, AF Daniyan, C Famulare, BM Cuello, TZ Horvat, O Abdel-Wahab, RL Levine, AD Viny, EM Stein, SF Cai, M Roshal, MS Tallman, AD Goldberg |
Blood Advances | 2021 |
|
Understanding CLL biology through mouse models of human genetics
E ten Hacken, CJ Wu |
Blood | 2021 |
|
SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
F Pozzo, T Bittolo, E Tissino, F Vit, E Vendramini, L Laurenti, G DArena, J Olivieri, G Pozzato, F Zaja, A Chiarenza, FD Raimondo, A Zucchetto, R Bomben, FM Rossi, GD Poeta, MD Bo, V Gattei |
Haematologica | 2020 |
|
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing
P Pararajalingam, KM Coyle, SE Arthur, N Thomas, M Alcaide, B Meissner, M Boyle, Q Qureshi, BM Grande, C Rushton, GW Slack, AJ Mungall, CS Tam, R Agarwal, SJ Dawson, G Lenz, S Balasubramanian, RD Gascoyne, C Steidl, J Connors, D Villa, TE Audas, MA Marra, NA Johnson, DW Scott, RD Morin |
Blood | 2020 |
|
Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns
AD Tang, CM Soulette, MJ van Baren, K Hart, E Hrabeta-Robinson, CJ Wu, AN Brooks |
Nature Communications | 2020 |
|
Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients
F de Fraipont, S Gazzeri, WC Cho, B Eymin |
Frontiers in Genetics | 2019 |
|
RNA-binding proteins in hematopoiesis and hematological malignancy
DJ Hodson, M Screen, M Turner |
Blood | 2019 |
|
Altered RNA Processing in Cancer Pathogenesis and Therapy
EA Obeng, C Stewart, O Abdel-Wahab |
Cancer Discovery | 2019 |
|
Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia
JM Pearson, SF Tan, A Sharma, C Annageldiyev, TE Fox, JL Abad, G Fabrias, D Desai, S Amin, HG Wang, MC Cabot, DF Claxton, M Kester, DJ Feith, TP Loughran |
Molecular cancer research : MCR | 2019 |
